Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Neurochemical Changes Induced By Transcranial Direct Current Stimulation In Patients With Schizophrenia
FY 2013-14
Summary
Schizophrenia is a psychiatric illness that affects approximately 1% of the world’s population. It is among the top ten causes of disability worldwide and results in enormous economic costs to the Canadian health care system. Patients with schizophrenia commonly suffer from delusions, defined as fixed and false beliefs, as well as hallucinations, which may include hearing imaginary voices or sounds. The symptoms of schizophrenia are thought to occur due to abnormal changes in the function of the brain.
The brain is primarily composed of cells called neurons, which, when alive, produce a chemical that is referred to as n-acetyl-aspartate (NAA). We can measure the amount of NAA present in the human brain and subsequently use this measurement to assess how therapies for mental illnesses affect the number of living neurons.
Neurons communicate with each other using chemicals that are collectively referred to as neurotransmitters. Glutamate is a highly abundant excitatory neurotransmitter that activates neurons. We can judge how active an area of the brain is by measuring the amount of glutamate it produces.
NAA and glutamate are essential to the normal function of the human brain. Previous research by our group has shown that patients with schizophrenia have notably different levels of NAA and glutamate as compared to healthy individuals. It is possible that these neurochemical changes contribute to the symptoms present in schizophrenia.
Schizophrenia does not have a cure and currently available drug treatments are only able to decrease symptom severity; they are unable to address the underlying cause of the illness. Furthermore, these medications are not completely effective and up to one third of patients do not respond to such treatments.
Transcranial direct current stimulation (tDCS) is an innovative treatment approach to schizophrenia that involves the usage of electrical stimulation to alter brain activity. tDCS is a non-invasive procedure in which the patient remains awake. Also, tDCS is not painful and is usually only noticeable because it can result in a light tingling sensation below the electrodes on the scalp. To perform tDCS, two electrodes are placed on the scalp: the anode, which causes an increase in brain activity, and the cathode, which causes a decrease in brain activity.
tDCS is an efficacious and safe alternative treatment for several other brain illnesses, including depression and Parkinson’s disease. tDCS was recently shown to significantly reduce hallucinations in schizophrenia, yet the mechanism through which the procedure exerts these effects is still unclear.
Our study aims to explore if the therapeutic effect of tDCS is associated with changes in NAA and glutamate. We hypothesize that stimulation by the anode, which increases the activity of underlying neurons, will lead to increases in both NAA and glutamate. Conversely, we hypothesize that stimulation by the cathode, which reduces the activity of underlying neurons, will lead to decreases in NAA and glutamate.
We will measure levels of NAA and glutamate before and after tDCS using an MRI procedure called magnetic resonance spectroscopy (MRS). MRS is a non-invasive technique that has been previously used to show anomalies in NAA and glutamate in patients with schizophrenia.
Our study seeks to determine how tDCS affects neurochemicals in patients with schizophrenia. Changes in the levels of NAA and glutamate will provide a mechanistic explanation for the beneficial effects of tDCS. The results will further contribute to the implementation of tDCS as a treatment alternative for patients with schizophrenia, ultimately improving the management and outcomes of the illness.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
311691
Name
Plitman Eric
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Neurochemical Changes Induced By Transcranial Direct Current Stimulation In Patients With Schizophrenia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Imaging; Electrical Stimulation; Glutamate; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mental Health; N-Acetyl-Aspartate; Neuroscience; Schizophrenia; Transcranial Direct Current Stimulation
Abstract
Schizophrenia is a psychiatric illness that affects approximately 1% of the world’s population. It is among the top ten causes of disability worldwide and results in enormous economic costs to the Canadian health care system. Patients with schizophrenia commonly suffer from delusions, defined as fixed and false beliefs, as well as hallucinations, which may include hearing imaginary voices or sounds. The symptoms of schizophrenia are thought to occur due to abnormal changes in the function of the brain.
The brain is primarily composed of cells called neurons, which, when alive, produce a chemical that is referred to as n-acetyl-aspartate (NAA). We can measure the amount of NAA present in the human brain and subsequently use this measurement to assess how therapies for mental illnesses affect the number of living neurons.
Neurons communicate with each other using chemicals that are collectively referred to as neurotransmitters. Glutamate is a highly abundant excitatory neurotransmitter that activates neurons. We can judge how active an area of the brain is by measuring the amount of glutamate it produces.
NAA and glutamate are essential to the normal function of the human brain. Previous research by our group has shown that patients with schizophrenia have notably different levels of NAA and glutamate as compared to healthy individuals. It is possible that these neurochemical changes contribute to the symptoms present in schizophrenia.
Schizophrenia does not have a cure and currently available drug treatments are only able to decrease symptom severity; they are unable to address the underlying cause of the illness. Furthermore, these medications are not completely effective and up to one third of patients do not respond to such treatments.
Transcranial direct current stimulation (tDCS) is an innovative treatment approach to schizophrenia that involves the usage of electrical stimulation to alter brain activity. tDCS is a non-invasive procedure in which the patient remains awake. Also, tDCS is not painful and is usually only noticeable because it can result in a light tingling sensation below the electrodes on the scalp. To perform tDCS, two electrodes are placed on the scalp: the anode, which causes an increase in brain activity, and the cathode, which causes a decrease in brain activity.
tDCS is an efficacious and safe alternative treatment for several other brain illnesses, including depression and Parkinson’s disease. tDCS was recently shown to significantly reduce hallucinations in schizophrenia, yet the mechanism through which the procedure exerts these effects is still unclear.
Our study aims to explore if the therapeutic effect of tDCS is associated with changes in NAA and glutamate. We hypothesize that stimulation by the anode, which increases the activity of underlying neurons, will lead to increases in both NAA and glutamate. Conversely, we hypothesize that stimulation by the cathode, which reduces the activity of underlying neurons, will lead to decreases in NAA and glutamate.
We will measure levels of NAA and glutamate before and after tDCS using an MRI procedure called magnetic resonance spectroscopy (MRS). MRS is a non-invasive technique that has been previously used to show anomalies in NAA and glutamate in patients with schizophrenia.
Our study seeks to determine how tDCS affects neurochemicals in patients with schizophrenia. Changes in the levels of NAA and glutamate will provide a mechanistic explanation for the beneficial effects of tDCS. The results will further contribute to the implementation of tDCS as a treatment alternative for patients with schizophrenia, ultimately improving the management and outcomes of the illness.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Plitman, Eric
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~